Clinical Validation Study Protocol for SmartEyes Smart Optometry Measurement Device (Medical Device Clinical Validation Study)

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-17
SponsorThe Hong Kong Polytechnic University

About this trial

This study aims to evaluate the SmartEyes smart refraction measurement device in two phases under real outpatient optometry room visits at Wuhan Children's Hospital. The first phase used a prospective, single-center, stratified paired cross-sectional clinical validation design, evaluating the consistency between SmartEyes, Topcon KR-800, and subjective refraction/post-dilation refraction results among outpatient children and adolescents without and those requiring dilation, and evaluating the repeatability of the three devices under corresponding conditions. The second phase added prospective cohort follow-up to explore the relationship between SmartEyes fine scale refractive data and axial length growth, evaluating whether these results better match or predict short-term axial growth trends than traditional 0.25D stepped objective refraction results.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged 6-17 years old, no gender limit;

Visiting the outpatient optometry room of Wuhan Children's Hospital, clinically required refraction examination;

Ability to cooperate in completing SmartEyes, Topcon KR-800, Topcon KR-1W examinations;

Able to complete reliable subjective refraction;

Disqualifiers

Those unable to maintain stable fixation, unable to cooperate with desktop equipment for examination, or unable to perform reliable subjective refraction;

Obvious strabismus, nystagmus, severe amblyopia, or other conditions affecting the reliability of objective/subjective refraction;

Keratoconus, obviously irregular astigmatism, corneal scarring, corneal edema, or other corneal diseases that significantly affect refractive measurement;

Moderate to severe cataracts, obvious lens opacity, vitreous opacity, fundus diseases, and other conditions that may affect the refraction endpoint;

Trial population

Pediatric and adolescent outpatients presenting for routine optometric examinations and refractive status evaluation at the clinical site.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • SmartEyes smart refraction measuring device

    Device

    Used to acquire objective optometric parameters, including refractive errors and corneal measurements, during the clinical evaluation and comparison protocol.

  • Topcon KR800

    Device

    Used to acquire objective optometric parameters, including refractive errors and corneal measurements, during the clinical evaluation and comparison protocol.

  • Subjective refraction

    Diagnostic test

    Routine refractive examination

  • IOL master 700

    Device

    FDA-certified equipment used for measuring the axial length

Treatment groups

200 Participants
are divided into 3 treatment groups
Group A: No pupil dilation subgroup(Phase I)3 interventions
Group B: Required pupil dilation subgroup(Phase I)3 interventions
Group C: Follow-up visit group (Phase II)4 interventions

Trial outcomes

Primary outcomes

1

Refractive Measurement Agreement and Repeatability across Subgroups

Evaluate the agreement between SmartEyes, Topcon KR-800, and subjective/cycloplegic reference refractions, as well as the independent measurement repeatability of each device, across both non-cycloplegic and cycloplegic subgroups. Assess whether the optical eye relaxation function of SmartEyes yields refractive outcomes closer to subjective and cycloplegic references than conventional objective methods.

Time frame
Phase I clinical evaluation (completed during the baseline outpatient examination sessions)

Secondary outcomes

1

Absolute axial length change measured by optical biometry

Absolute change in axial length (unit: mm) measured by optical biometry device.

Time frame
From baseline through the Phase II longitudinal follow-up period (6 months)
2

Axial length growth rate measured by optical biometry

Axial length monthly growth rate (unit: mm/month), derived from serial axial-length measurements obtained by optical biometry device.

Time frame
From baseline through the Phase II longitudinal follow-up period (6 months)
3

Correlation between fine-graded refractive change and absolute axial length change

Pearson correlation coefficient between fine-graded spherical equivalent change (SmartEyes autorefractor, diopter) and absolute axial-length change (optical biometry, mm).

Time frame
From baseline through the Phase II longitudinal follow-up period (6 months)

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: